BiomX, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Tables)

6 Months Ended

Jun. 30, 2022

Warrant

Issuance Date

Expiration
Date

Exercise
Price
Per Share

Number of
Shares of
Common Stock
Underlying
Warrants

Private Placement Warrants

IPO (December 13, 2018)

December 13, 2023

11.50

2,900,000

Public Warrants

IPO (December 13, 2018)

October 28, 2024

11.50

3,500,000

2021 Registered Direct Offering Warrants

SPA (July 28, 2021)

January 28, 2027

5.00

2,812,501

9,212,501

	Six Months Ended June 30,
	2022		2021
Underlying value of Common Stock ($)		0.66-1.41		7.02
Exercise price ($)		0.66-1.41		7.02
Expected volatility (%)		85.3-87.0		85.0
Expected terms of the option (years)		6.11		6.11
Risk-free interest rate (%)		2.50-3.39		1.17

	For the Six Months Ended June 30 2022
	Number of Options			Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at the beginning of period		4,084,549		$	3.95	$	671
Granted		1,504,000		$	1.25
Forfeited		(622,559	)	$	4.07
Exercised		-		$	-
Outstanding at the end of period		4,965,990		$	3.12	$	1,196
Exercisable at the end of period		2,699,833
Weighted average remaining contractual life of outstanding options – years as of June 30, 2022		7.24

	Six Months Ended June 30,				Three Months Ended June 30,
	2022		2021		2022			2021
Research and development expenses, net		248		958		(10	)		627
General and administrative		551		667		194			468
		799		1,625		184			1,095

Warrant

Issuance Date

Expiration
Date

Exercise
Price
Per Share

Number of
Shares of
Common Stock
Underlying
Warrants

Private Warrants issued to scientific founders (see below)

November 27, 2017

2,974